Peptide drug development has made great progress in the last decade thanks to new
production, modification, and analytic technologies. Peptides have been produced and …

Abstract Treatment of migraine is on the cusp of a new era with the development of drugs
that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its …

Migraine is an extremely disabling, common neurological disorder characterized by a
complex neurobiology, involving a series of central and peripheral nervous system areas …

Background We tested erenumab, a fully human monoclonal antibody that inhibits the
calcitonin gene–related peptide receptor, for the prevention of episodic migraine. Methods …

Background Rimegepant, a small molecule calcitonin gene-related peptide receptor
antagonist, has shown efficacy in the acute treatment of migraine using a standard tablet …

Plaguing humans for more than two millennia, manifest on every continent studied, and with
more than one billion patients having an attack in any year, migraine stands as the sixth …

Migraine is one of the most prevalent and disabling diseases worldwide, but until recently,
few migraine-specific therapies had been developed. Extensive basic and clinical scientific …

Background Ubrogepant is an oral, small-molecule calcitonin gene–related peptide receptor
antagonist for acute migraine treatment. Methods We conducted a randomized trial to …

Importance Ubrogepant is an oral calcitonin gene–related peptide receptor antagonist under
investigation for acute treatment of migraine. Objective To evaluate the efficacy and …

Background Calcitonin gene–related peptide receptor has been implicated in the
pathogenesis of migraine. Rimegepant is an orally administered, small-molecule, calcitonin …